AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment

International trial marks leap forward in chemotherapy-induced neuropathy care

In a landmark announcement from Paris, AlgoTherapeutix (AlgoTx) has heralded the successful completion of its international phase 2 trial for ATX01, a novel therapeutic aimed at treating chemotherapy-induced peripheral neuropathy (CIPN).

The trial, named ‘ACT’, reached its ‘Last Patient Last Visit’ milestone, a critical step in the development of this promising non-opioid pain relief medication.

Under the stewardship of Professor Guido Cavaletti of the University of Milano-Bicocca, the ACT trial spanned over 40 sites across the US and Europe. It was designed as a double-blind, placebo-controlled study to rigorously assess the efficacy and safety of ATX01 in patients grappling with CIPN—a debilitating side effect of certain cancer treatments.

Stéphane Thiroloix, AlgoTx’s Founder, President & CEO, expressed his enthusiasm: “We’re delighted with the solid progress of our ACT clinical trial and commend the patients, investigators, and AlgoTx clinical team for their dedication in achieving this major milestone.”

CIPN is a significant challenge for two-thirds of chemotherapy patients, often resulting in severe pain due to nerve degeneration. Philippe Picaut, AlgoTx’s Chief Development Officer, emphasized the importance of this development: “CIPN represents a high unmet need without any approved treatments. Any progress in this field is therefore very gratifying.”

ATX01’s innovative approach involves targeting specific nociceptive sodium channels related to pain signaling. Its local application is designed to provide effective pain relief while minimizing systemic exposure, thus reducing potential toxicity.

As the biotech community eagerly anticipates the detailed results of the ACT trial, this development signifies a beacon of hope for those affected by CIPN, potentially transforming the landscape of neuropathic pain management in cancer care.